Social Anxiety Disorders (SAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
NEW YORK, April 24, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Social Anxiety Disorders (SAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
http://www.reportlinker.com/p0842994/Social-Anxiety-Disorders-SAD-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Social Anxiety Disorders (SAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary
GlobalData, the industry analysis specialist, has released its new report, "Social Anxiety Disorders (SAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Social Anxiety Disorders (SAD) Therapeutics market. The report identifies the key trends shaping and driving the global Social Anxiety Disorders (SAD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Social Anxiety Disorders (SAD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Social Anxiety Disorders (SAD) Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Social Anxiety Disorders (SAD) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Social Anxiety Disorders (SAD) Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Social Anxiety Disorders (SAD) Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Social Anxiety Disorders (SAD) Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Social Anxiety Disorders (SAD) Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Social Anxiety Disorders (SAD) Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Social Anxiety Disorders (SAD) Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Social Anxiety Disorders (SAD) Therapeutics - Introduction 7
2.1 Overview 7
2.1.1 Types of SAD 7
2.2 Etiology and Pathophysiology 7
2.3 Epidemiology 8
2.3.1 The US 8
2.3.2 Spain 8
2.3.3 Italy 8
2.3.4 Japan 8
2.3.5 Germany 8
2.3.6 France 8
2.3.7 Pharmaco-economic Burden 8
2.3.8 Quality of Life (QoL) 8
2.3.9 Morbidity 9
2.4 Symptoms 9
2.5 Diagnosis 9
2.5.1 Diagnostic Criteria for SAD Defined by DSM-IV 9
2.5.2 Measurement Scales 10
2.6 Treatment and Management Pattern 10
2.6.1 Psychological Treatment 10
2.6.2 Pharmacologic Treatment 11
2.7 Referral Pathway 12
2.8 GlobalData Pipeline Report Guidance 13
3 SAD Therapeutics - Market Characterization 14
3.1 Overview 14
3.2 SAD Therapeutics Market Size (2006-2011) - Global 14
3.3 SAD Therapeutics Market Forecast (2011-2019) - Global 16
3.4 SAD Therapeutics Market Size (2006-2011) - The US 17
3.5 SAD Therapeutics Market Forecast (2011-2019) - The US 18
3.6 SAD Therapeutics Market Size (2006-2011) - France 19
3.7 SAD Therapeutics Market Forecast (2011-2019) - France 20
3.8 SAD Therapeutics Market Size (2006-2011) - Germany 21
3.9 SAD Therapeutics Market Forecast (2011-2019) - Germany 22
3.10 SAD Therapeutics Market Size (2006-2011) - Italy 23
3.11 SAD Therapeutics Market Forecast (2011-2019) - Italy 24
3.12 SAD Therapeutics Market Size (2006-2011) - Spain 25
3.13 SAD Therapeutics Market Forecast (2011-2019) - Spain 26
3.14 SAD Therapeutics Market Size (2006-2011) - The UK 27
3.15 SAD Therapeutics Market Forecast (2011-2019) - The UK 28
3.16 SAD Therapeutics Market Size (2006-2011) - Japan 29
3.17 SAD Therapeutics Market Forecast (2011-2019) - Japan 30
3.18 Drivers and Barriers 31
3.18.1 Drivers for the SAD Therapeutics Market 31
3.18.2 Barriers for the SAD Therapeutics Market 31
3.19 Opportunity and Unmet Needs 31
3.20 Key Takeaway 32
4 SAD Therapeutics Market - Competitive Assessment 33
4.1 Overview 33
4.2 Strategic Competitor Assessment 33
4.3 Product Profile for the Major Marketed Products in the SAD Therapeutics Market 34
4.3.1 SSRIs 34
4.3.2 SNRIs 34
4.3.3 Benzodiazepines 36
4.3.4 Monoamine Oxidase Inhibitors 37
4.4 Key Takeaway 37
5 SAD Therapeutics - Pipeline Assessment 38
5.1 Overview 38
5.2 Strategic Pipeline Assessment 38
5.3 Pipeline by Phases of Development 38
5.3.1 SAD Therapeutics-Phase II Pipeline 38
5.3.2 SAD Therapeutics- Phase I Pipeline 39
5.4 SAD Therapeutics Market - Clinical Pipeline by Mechanism of Action. 39
5.5 Technology Trends Analytic Framework 40
5.6 Promising Drugs under Clinical Development 41
5.7 Profiles of Promising Drugs 42
5.7.1 CXB722 42
5.7.2 PH94B 42
5.7.3 TGW00AA 43
5.8 Key Takeaway 44
6 SAD Therapeutics - Clinical Trials Mapping 45
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 45
6.2 Clinical Trials by Phase 46
6.3 Clinical Trials by Trial Status 47
6.4 Prominent Sponsors 48
6.5 Top Companies Participating in Therapeutics Clinical Trials 50
7 SAD Therapeutics - Strategic Assessment 51
7.1 Key Events Impacting the Future Market 51
7.2 Future Market Competition Scenario 51
8 SAD Therapeutics - Future Players 53
8.1 Introduction 53
8.2 Company Profiles 54
8.2.1 CeNeRx BioPharma 54
8.2.2 Fabre-Kramer Pharmaceuticals, Inc 54
8.2.3 Pherin Pharmaceuticals 55
8.3 Other Companies in the SAD Therapeutics Market 56
9 SAD Therapeutics - Licensing and Partnership Deals 57
10 Appendix 58
10.1 Market Definitions 58
10.2 Abbreviations 58
10.3 Methodology 59
10.3.1 Coverage 59
10.3.2 Secondary Research 59
10.3.3 Forecasting 60
10.3.4 Primary Research 62
10.3.5 Expert Panel Validation 63
10.4 Contact Us 63
10.5 Disclaimer 63
10.6 Bibliography 63
List of Tables
Table 1: FDA and EMEA Approved Medications for the Treatment of SAD 12
Table 2: SAD Therapeutics Market, Global, Revenue ($m), 2006-2011 15
Table 3: SAD Therapeutics Market, Global, Forecast ($m), 2011-2019 16
Table 4: SAD Therapeutics Market, The US, Revenue ($m), 2006-2011 17
Table 5: SAD Therapeutics Market, The US, Forecast ($m), 2011-2019 18
Table 6: SAD Therapeutics Market, France, Revenue ($m), 2006-2011 19
Table 7: SAD Therapeutics Market, France, Forecast ($m), 2011-2019 20
Table 8: SAD Therapeutics Market, Germany, Revenue ($m), 2006-2011 21
Table 9: SAD Therapeutics Market, Germany, Forecast ($m), 2011-2019 22
Table 10: SAD Therapeutics Market, Italy, Revenue ($m), 2006-2011 23
Table 11: SAD Therapeutics Market, Italy, Forecast ($m), 2011-2019 24
Table 12: SAD Therapeutics Market, Spain, Revenue ($m), 2006-2011 25
Table 13: SAD Therapeutics Market, Spain, Forecast ($m), 2011-2019 26
Table 14: SAD Therapeutics Market, The UK, Revenue ($m), 2006-2011 27
Table 15: SAD Therapeutics Market, The UK, Forecast ($m), 2011-2019 28
Table 16: SAD Therapeutics Market, Japan, Revenue ($m), 2006-2011 29
Table 17: SAD Therapeutics Market, Japan, Forecast ($m), 2011-2019 30
Table 18: Treatment-Emergent Adverse Event Incidence in Short-Term Placebo-Controlled Effexor XR Clinical Trials in SAD Patients 35
Table 19: SAD Therapeutics-Phase II Pipeline 38
Table 20: SAD Therapeutics-Phase I Pipeline 39
Table 21: SAD Therapeutics - Most Promising Drugs Under Clinical Development, 2011 41
Table 22: SAD Therapeutics Market, Number of Clinical Trials by Region, 2011 45
Table 23: SAD Therapeutics Market, Global, Clinical Trials by Phase of Development (%), 2011 46
Table 24: SAD Therapeutics Market, Global, Clinical Trials by Trial Status (%), 2011 47
Table 25: SAD Therapeutics Market, Global, Clinical Trials by Prominent Sponsors (%), 2011 49
Table 26: SAD Therapeutics Market, Global, Number of Clinical Trials by Top Companies, 2011 50
Table 27: CeNeRx BioPharma - CNS Pipeline Products, 2011 54
Table 28: CeNeRx BioPharma - SAD Pipeline Products, 2011 54
Table 29: Fabre-Kramer Pharmaceuticals - CNS Pipeline Products, 2011 55
Table 30: Fabre-Kramer Pharmaceuticals - SAD Pipeline Products, 2011 55
Table 31: Pherin Pharmaceuticals - CNS Pipeline Products, 2011 55
Table 32: Pherin Pharmaceuticals - SAD Pipeline Products, 2011 55
Table 33: SAD Therapeutics Market - Future Players, 2011 56
Table 34: SAD Therapeutics, Global, Deals, 2009-2011 57
List of Figures
Figure 1: SAD Treatment Options 11
Figure 2: Referral Pathway for SAD 12
Figure 3: SAD Therapeutics Market, Global, Revenue ($m), 2006-2011 14
Figure 4: SAD Therapeutics Market, Global, Forecast ($m), 2011-2019 16
Figure 5: SAD Therapeutics Market, The US, Revenue ($m), 2006-2011 17
Figure 6: SAD Therapeutics Market, The US, Forecast ($m), 2011-2019 18
Figure 7: SAD Therapeutics Market, France, Revenue ($m), 2006-2011 19
Figure 8: SAD Therapeutics Market, France, Forecast ($m), 2011-2019 20
Figure 9: SAD Therapeutics Market, Germany, Revenue ($m), 2006-2011 21
Figure 10: SAD Therapeutics Market, Germany, Forecast ($m), 2011-2019 22
Figure 11: SAD Therapeutics Market, Italy, Revenue ($m), 2006-2011 23
Figure 12: SAD Therapeutics Market, Italy, Forecast ($m), 2011-2019 24
Figure 13: SAD Therapeutics Market, Spain, Revenue ($m), 2006-2011 25
Figure 14: SAD Therapeutics Market, Spain, Forecast ($m), 2011-2019 26
Figure 15: SAD Therapeutics Market, The UK, Revenue ($m), 2006-2011 27
Figure 16: SAD Therapeutics Market, The UK, Forecast ($m), 2011-2019 28
Figure 17: SAD Therapeutics Market, Japan, Revenue ($m), 2006-2011 29
Figure 18: SAD Therapeutics Market, Japan, Forecast ($m), 2011-2019 30
Figure 19: Opportunity and Unmet Need in the SAD Therapeutics Market, 2011 32
Figure 20: Strategic Competitor Assessment of the Major Marketed Products in SAD, 2011 33
Figure 21: SAD Therapeutics Pipeline by Phases of Clinical Development (%), 2011 38
Figure 22: SAD Therapeutics, Clinical Pipeline by Mechanism of Action (%), 2011 39
Figure 23: Technology Trends Analytic Framework of the SAD Therapeutics Pipeline, 2011 40
Figure 24: Technology Trends Analytic Framework of the SAD Therapeutics Pipeline - Description, 2011 41
Figure 25: CXB722 Clinical Trial Details 42
Figure 26: PH94B Clinical Trial Details 43
Figure 27: TWG00AA Clinical Trial Details 43
Figure 28: SAD Therapeutics Market, Number of Clinical Trials by Region, 2011 45
Figure 29: SAD Therapeutics Market, Global, Clinical Trials by Phase of Development (%), 2011 46
Figure 30: SAD Therapeutics Market, Global, Clinical Trials by Trial Status (%), 2011 47
Figure 31: SAD Therapeutics Market, Global, Clinical Trials by Overall Sponsors (%), 2011 48
Figure 32: SAD Therapeutics Market, Global, Clinical Trials by Prominent Sponsors (%), 2011 49
Figure 33: SAD Therapeutics Market, Global, Number of Clinical Trials by Top Companies, 2011 50
Figure 34: SAD Therapeutics Market, Drivers and Restraints, 2011 51
Figure 35: Implications for Future Market Competition in the SAD Therapeutics Market, 2011 52
Figure 36: SAD Therapeutics Market, Clinical Pipeline by Company, 2011 53
Figure 37: GlobalData Market Forecasting Model 62
Companies mentioned
CeNeRx BioPharma
Fabre-Kramer Pharmaceuticals, Inc
Pherin Pharmaceuticals
To order this report:
Therapy Industry: Social Anxiety Disorders (SAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article